ReviewJournal of translational medicine2026
Chimeric antigen receptor T‑cell therapy in chronic viral infections: a review.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond Oncology: Exploring the Expanding Role of CAR T Cell Therapy in Autoimmune and Infectious Diseases-A Systematic Review.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Recent advances in molecular mechanisms to improve the efficacy of CAR-T cell therapy for viral diseases, cancer, and autoimmune diseases.Stem cell research & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the success of vaccination and small-molecule antivirals in significantly reducing mortality from acute viral infections, chronic viral infections such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), cytomegalovirus (CMV), and Epstein–Barr virus (EBV) remain persistent global health burdens. Latent reservoirs, drug resistance mutations, and immune evasion mechanisms enable these viruses to persist, highlighting the need for novel therapeutic approaches. Chimeric antigen receptor T-cell (CAR-T) therapy is an emerging immunotherapeutic strategy, initially developed to treat cancer, that harnesses a patient’s own immune cells to induce targeted immune responses. Chronic viral infections share significant similarities with tumors, including immune cell exhaustion, expression of inhibitory ligands, and metabolic suppression. Consequently, CAR-T-cell therapy holds promise as a new approach to treating chronic viral infections and has attracted considerable attention in recent years. This review systematically evaluates the progress in using CAR-T-cell therapy to treat chronic infections caused by HIV, HBV, CMV, and EBV, focusing on target selection and CAR-T-cell design strategies and highlighting the potential of these approaches to achieve disease control.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.